Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 7,443 matching trials from the live ClinicalTrials.gov search.

Filters: Aurora, Colorado Clear all

Conditions: Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions: Levocarnitine tartrate, cilostazol; Dietary Supplement · Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more

Conditions: Type 1 Diabetes
Interventions: Pump suspension; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Prostate Cancer
Interventions: Galeterone, Enzalutamide; Drug
Lead sponsor: LTN PHARMACEUTICALS, INC.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 51
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions: PF-08634404, Chemotherapy, Nivolumab; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 83
States / cities: Atascadero, California • Burbank, California • Encino, California + 68 more

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Obeticholic Acid (OCA), Placebo; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 33
States / cities: Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 24 Hours to 25 Years
Enrollment: 171 participants
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Docetaxel, Echocardiography Test, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 611
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more

Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions: Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 390
States / cities: Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more

Conditions: Advanced Cancer
Interventions: BMS-986178, Nivolumab, Ipilimumab, Tetanus vaccine, DPV-001 vaccine, Cyclophosphamide; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Hackensack, New Jersey + 4 more

Conditions: Leukemia
Interventions: clofarabine, cytarabine, methotrexate, laboratory biomarker analysis; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Downey, California • Long Beach, California + 65 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more

Conditions: Chronic Kidney Diseases
Interventions: COR-001, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Embolism and Thrombosis
Interventions: EkoSonic Endovascular System with thrombolytic; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 65
States / cities: Glendale, Arizona • Los Angeles, California • Englewood, Colorado + 54 more

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: Diabetes Mellitus
Interventions: Dexcom Continuous Glucose Monitoring System; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: Chula Vista, California • Escondido, California • Santa Barbara, California + 7 more

Conditions: Diabetic Nephropathy, Diabetic Kidney Disease
Interventions: Pyridorin, Placebo; Drug
Lead sponsor: NephroGenex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 47 more

Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Drug · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 90
States / cities: Homewood, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 72 more

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, radiation therapy; Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 228
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Fresno, California + 164 more

Conditions: Brain Metastases, Lung Cancer
Interventions: Brigatinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Duarte, California • Aurora, Colorado • Rochester, Minnesota

Conditions: Cancer
Interventions: Navigation; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Alamosa, Colorado • Aurora, Colorado • Denver, Colorado + 2 more

Conditions: Lung Cancer
Interventions: carboplatin, gefitinib, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 65 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 140
States / cities: Scottsdale, Arizona • Fort Collins, Colorado • Jacksonville, Florida + 88 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 183
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 144 more

Conditions: Cannabis Use Disorder
Interventions: Dronabinol Pill, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Failure
Interventions: Finerenone, Empagliflozin; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 46
States / cities: Fairhope, Alabama • Phoenix, Arizona • Chula Vista, California + 40 more

Search by objective public record fields.

Evaluation of Cilostazol in Combination With L-Carnitine

An Outpatient Pump Shutoff Pilot Feasibility and Safety Study

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)

Genetic Collection Protocol

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

An International Pulmonary Embolism Registry Using EKOS

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Evaluation of the Safety and Effectiveness of the Dexcom Continuous Glucose Monitoring (CGM) System

Pyridorin in Diabetic Nephropathy

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Brigatinib Before Brain Irradiation Trial (B3i Trial)

Apoyo Con Carino: Patient Navigation for Palliative Care

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Effects of THC on Alcohol Consumption and Neural Correlates of Reward

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)